Citation Impact
Citing Papers
Breast Cancer Treatment Outcome With Adjuvant Tamoxifen Relative to Patient CYP2D6 and CYP2C19 Genotypes
2007
Breast cancer
2019 Standout
CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen
2010
Cancer treatment and survivorship statistics, 2022
2022 Standout
Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy
2010
Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs)
2011
Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review
2012 Standout
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
2013 Standout
Polymorphism of human cytochrome P450 enzymes and its clinical impact
2009
Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma
2011
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
2008 Standout
Oral Anticoagulant Therapy
2012 Standout
Nutrition and physical activity guidelines for cancer survivors
2012 Standout
CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
2012
Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy
2008
Natural Disruption of Group 2 Phospholipase A2 Gene Protects Against Choline-deficient Ethionine-supplemented Diet-induced Acute Pancreatitis and Lung Injury
2005
Cytochrome P450 pharmacogenetics and cancer
2006
Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy
2007
Management of menopausal symptoms in patients with breast cancer: an evidence-based approach
2005
Update on Prevalence of Pain in Patients With Cancer: Systematic Review and Meta-Analysis
2016 Standout
Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects
2007
Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis
2014 Standout
Adherence to Adjuvant Hormonal Therapy and Its Relationship to Breast Cancer Recurrence and Survival Among Low-income Women
2012
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
CYP2C9 Genotype-guided Warfarin Prescribing Enhances the Efficacy and Safety of Anticoagulation: A Prospective Randomized Controlled Study
2007
CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
2012
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
2006
Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients
2011
The phospholipase A2 superfamily and its group numbering system
2006 Standout
Metabolism of Antidepressant and Neuroleptic Drugs by Cytochrome P450s: Clinical and Interethnic Aspects
2007
The Discovery and Development of Selective Estrogen Receptor Modulators (SERMs) for Clinical Practice
2013
PROTAC targeted protein degraders: the past is prologue
2022 Standout
Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy
2013 Standout
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients
2009
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes
2011
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and Age
2011
Mining electronic health records: towards better research applications and clinical care
2012 Standout
Modifiable Risk Factors for Breast Cancer Recurrence: What Can We Tell Survivors?
2007
Chemical Constituents and Pharmacological Activities of Garlic (Allium sativum L.): A Review
2020 Standout
Estrogen Receptors as Therapeutic Targets in Breast Cancer
2008
Practical Recommendations for Pharmacogenomics-based Prescription: 2010 ESF–UB Conference on Pharmacogenetics and Pharmacogenomics
2010
Effect of Concomitant CYP2D6 Inhibitor Use and Tamoxifen Adherence on Breast Cancer Recurrence in Early-Stage Breast Cancer
2010
Pharmacogenomics of Tamoxifen Therapy
2009
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
2014 Standout
Cancer treatment and survivorship statistics, 2016
2016 Standout
Pharmacogenetic testing among patients with mood and anxiety disorders is associated with decreased utilization and cost: A propensity-score matched study
2018 StandoutNobel
Cancer treatment and survivorship statistics, 2019
2019 Standout
Cytochrome P450 enzyme mediated herbal drug interactions (Part 2).
2014
American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline
2015
Coprescription of Tamoxifen and Medications That Inhibit CYP2D6
2010
Drug Resistance in Cancer: An Overview
2014 Standout
Works of H Ho being referenced
CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment
2005
The role of phospholipase a2 in pancreatic acinar cell injury
1991